

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc.

October 15, 2015

LAVAL, Quebec, Oct. 15, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX) today announced that it has completed the previously announced acquisition of Synergetics USA, Inc. ("Synergetics"). Synergetics is a leading supplier of precision surgical devices. Synergetics' primary focus is on the surgical disciplines of ophthalmology and neurosurgery.

About Valeant Pharmaceuticals International, Inc.

Valeant is a multinational, specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products and medical devices primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at

www.valeant.com

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Elif McDonald
905-695-7607
elif.mcdonald@valeant.com

To view the original version on PR Newswire, visit:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-international-inc-completes-acquisition-of-synergetics-usa-inc-300160574.html>

SOURCE Valeant Pharmaceuticals International, Inc.

Investor Inquiries

ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)



[RSS FEED](#)

Media inquiries

Corporate.communications@bauschhealth.com

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION